Rangering i aksjer
#16218
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Aksjekurs
$3.70
Sist synkronisert: 2026-07-31
Handel Opus Genetics, Inc. (IRD)
Pris IRD pris med markedsverdi på B
Markedsverdi av Opus Genetics, Inc.(IRD)
Markedsverdi: $305.87M
Per September 2026 har Opus Genetics, Inc. en markedsverdi på $305.87M. Dette gjør Opus Genetics, Inc. til det 16218th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Opus Genetics, Inc. fra 2024 til 2026
IRD sammenlignet med topp 5 mest populære stocks
| Pris på IRD |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.260T
|
+1,719,438.14%
|
|
|
|
|
$4.779T
|
+1,562,157.96%
|
|
|
|
|
$4.017T
|
+1,313,103.81%
|
|
|
|
|
$3.719T
|
+1,215,863.74%
|
|
|
|
|
$2.734T
|
+893,812.25%
|
